INSTRUCTIONS FOR USE

This Drug Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document may differ greatly from the standard benefit plan upon which this Drug Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Drug Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Drug Policy. Other Policies and Coverage Determination Guidelines may apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary. This Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

BENEFIT CONSIDERATIONS

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. See the Policy and Procedure addressing the treatment of serious rare diseases.

Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.
Xolair (omalizumab) for subcutaneous use is proven for:

I. Patients with moderate to severe persistent asthma who meet all of the following criteria:
   A. Have a positive skin test or in vitro reactivity to a perennial aeroallergen.
   B. Symptoms inadequately controlled with inhaled corticosteroids.
   C. Have a baseline plasma immunoglobulin E (IgE) level greater than or equal to 30 IU/mL and less than or equal to 1500 IU/mL.

Xolair is medically necessary when all of the following criteria are met:
A. Diagnosis of moderate or severe asthma; and
B. Classification of asthma as uncontrolled or inadequately controlled as defined by at least one of the following:
   1. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20); or
   2. Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months; or
   3. Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment); or
   4. Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal])
   and
C. Baseline (pre-omalizumab treatment) serum total IgE level greater than or equal to 30 IU/mL and less than or equal to 1500 IU/mL; and
D. Positive skin test or in vitro reactivity to a perennial aeroallergen; and
E. Used in combination with one of the following:
   1. One maximally-dosed (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) product [e.g., fluticasone propionate/salmeterol (Advair®), budesonide/formoterol (Symbicort®)]; or
   2. Combination therapy including both of the following:
      a. One high-dose (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco®), mometasone furoate (Asmanex®), beclomethasone dipropionate (QVAR®)]; and
      b. One additional asthma controller medication [e.g., LABA - olodaterol (Striverdi®) or indacaterol (Arcapta®); leukotriene receptor antagonist – montelukast (Singular®); theophylline]
   and
F. Patient is not receiving Xolair in combination with either of the following:
   1. Anti-interleukin 4 therapy [e.g. Dupixent (dupilumab)]
   2. Anti-interleukin 5 therapy [e.g. Nucala (mepolizumab), Cinquaer (resilizumab), Fasenra (benralizumab)]
   and
G. Xolair dosing for moderate to severe persistent asthma is in accordance with the United States Food and Drug Administration approved labeling; and
H. Prescribed by or in consultation with an allergist/immunologist or pulmonologist; and
I. Initial authorization will be for no more than 6 months.

Reauthorization/Continuation of Care Criteria
For patients currently on Xolair for the treatment of moderate to severe persistent asthma, authorization for continued use will be approved based on all of the following criteria:
A. Documentation of positive clinical response as demonstrated by at least one of the following:
   1. Reduction in the frequency of exacerbations
   2. Decreased utilization of rescue medications
   3. Increase in percent predicted FEV1 from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
   and
B. Used in combination with an ICS-containing controller medication; and
C. Patient is not receiving Xolair in combination with either of the following:
   1. Anti-interleukin 4 therapy [e.g. Dupixent (dupilumab)]
   2. Anti-interleukin 5 therapy [e.g. Nucala (mepolizumab), Cinquaer (resilizumab), Fasenra (benralizumab)]
   and
D. Xolair dosing for moderate to severe persistent asthma is in accordance with the United States Food and Drug Administration approved labeling; and
E. Prescribed by or in consultation with allergist/immunologist or pulmonologist; and
F. Reauthorization will be for no more than 12 months.
II. Patients with chronic urticaria who continue to remain symptomatic despite H1 antihistamine [e.g., cetirizine (Zyrtec), fexofenadine (Allegra)] treatment:

**Xolair is medically necessary** when all of the following criteria are met:

A. Diagnosis of chronic urticaria; and
B. One of the following:
   1. Patient remains symptomatic despite at least a 2-week trial of, or history of contraindication or intolerance to, two H1-antihistamines [e.g., Allegra (fexofenadine), Benadryl (diphenhydramine), Claritin (loratadine)]*; or
   2. Patient remains symptomatic despite at least a 2-week trial of, or history of contraindication or intolerance to both of the following taken in combination:
      a. A second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]; and
      b. One of the following:
         i. Different second generation H1-antihistamine [e.g., Allegra (fexofenadine), Claritin (loratadine), Zyrtec (cetirizine)]
         ii. First generation H1-antihistamine [e.g., Benadryl (diphenhydramine), Chlor-Trimeton (chlorpheniramine), Vistaril (hydroxyzine)]*
         iii. H2-antihistamine [e.g., Pepcid (famotidine), Tagamet HB (cimetidine), Zantac (ranitidine)]
         iv. Leukotriene modifier [e.g., Singular (montelukast)]

C. Xolair dosing for chronic urticaria is in accordance with the United States Food and Drug Administration approved labeling; and
D. Prescribed by or in consultation with an allergist/immunologist or dermatologist; and
E. Initial authorization will be for no more than 6 months.

**Reauthorization/Continuation of Care Criteria**

For patients currently on Xolair for the treatment of chronic urticaria, authorization for continued use will be approved based on all of the following criteria:

A. Documentation of positive clinical response (e.g., reduction in exacerbations, itch severity, hives); and
B. Xolair dosing for chronic urticaria is in accordance with the United States Food and Drug Administration approved labeling; and
C. Prescribed by or in consultation with an allergist/immunologist or dermatologist; and
D. Reauthorization will be for no more than 12 months.

*Note: Patients 65 years of age and older in whom first generation H1-antihistamines are considered high risk medications to be avoided (e.g., Beers criteria, HEDIS) should be directed to try alternatives that are not considered high risk.

**Xolair is unproven and not medically necessary in the following:**

- Seasonal allergic rhinitis
- Perennial allergic rhinitis
- Atopic dermatitis
- Peanut allergy
- Acute bronchospasm or status asthmaticus

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Xolair is approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents 6 years of age and older, who have moderate to severe persistent asthma and a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair is not indicated for acute bronchospasm or status asthmaticus. Xolair is also approved for chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment. It is not indicated for other allergic conditions or other forms of urticaria. Because of the risk of anaphylaxis, healthcare providers administering Xolair should observe patients closely for an appropriate period of time and be prepared to manage anaphylaxis that can be life-threatening.

On September 26, 2014, the U.S. FDA released a drug safety alert entitled: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, FDA has added information about these potential risks to the drug label. Additionally, reviewers found no difference in the rates of cancer between those patients being treated with Xolair and those who were not being treated with Xolair. However, due to limitations in the 5-year study, FDA cannot rule out a potential risk of cancer with Xolair, so this information was added to the Warnings and Precautions section of the drug label.
BACKGROUND

Asthma is a common chronic inflammatory disease of the airways that affects an estimated 24 million adults and children and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds to human immunoglobulin E (IgE)’s high affinity Fc receptor, thereby preventing the binding of IgE to a variety of cells associated with the allergic response. Preventing the bridging between IgE and cells associated with allergic response prevents degranulation of such cells and, thereby, the release of inflammatory mediators. Omalizumab has been found in clinical trials to reduce free serum IgE concentrations by more than 90%, considerably suppress eosinophils in induced sputum, and blunt both early and late phase allergic reactions.33-34

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2357</td>
<td>Injection, omalizumab, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J44.1</td>
<td>Chronic obstructive pulmonary disease with (acute) exacerbation</td>
</tr>
<tr>
<td>J44.9</td>
<td>Chronic obstructive pulmonary disease, unspecified</td>
</tr>
<tr>
<td>J45.40</td>
<td>Moderate persistent asthma, uncomplicated</td>
</tr>
<tr>
<td>J45.41</td>
<td>Moderate persistent asthma with (acute) exacerbation</td>
</tr>
<tr>
<td>J45.50</td>
<td>Severe persistent asthma, uncomplicated</td>
</tr>
<tr>
<td>J45.51</td>
<td>Severe persistent asthma with (acute) exacerbation</td>
</tr>
<tr>
<td>J45.909</td>
<td>Unspecified asthma, uncomplicated</td>
</tr>
<tr>
<td>J45.998</td>
<td>Other asthma</td>
</tr>
<tr>
<td>L50.0</td>
<td>Allergic urticaria</td>
</tr>
<tr>
<td>L50.1</td>
<td>Idiopathic urticaria</td>
</tr>
<tr>
<td>L50.8</td>
<td>Other urticaria</td>
</tr>
</tbody>
</table>

Maximum Dosage Requirements

Maximum Allowed Quantities by HCPCS Units

This section provides information about the maximum dosage per administration for omalizumab administered by a medical professional.

<table>
<thead>
<tr>
<th>Medication Name</th>
<th>Diagnosis</th>
<th>Maximum Dosage per Administration</th>
<th>HCPCS Code</th>
<th>Maximum Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xolair Omalizumab</td>
<td>Moderate to Severe Asthma</td>
<td>375 mg</td>
<td>J2357</td>
<td>90 HCPCS units</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(5 mg per unit)</td>
</tr>
<tr>
<td>Xolair Omalizumab</td>
<td>Chronic Urticaria</td>
<td>300 mg</td>
<td>J2357</td>
<td>60 HCPCS units</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(5 mg per unit)</td>
</tr>
</tbody>
</table>

Maximum Allowed Quantities by National Drug Code (NDC) Units

The allowed quantities in this section are calculated based upon both the maximum dosage information supplied within this policy as well as the process by which NDC claims are billed. This list may not be inclusive of all available NDC’s for each drug product and is subject to change.

<table>
<thead>
<tr>
<th>Medication Name</th>
<th>Diagnosis</th>
<th>How Supplied</th>
<th>National Drug Code</th>
<th>Maximum Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xolair Omalizumab</td>
<td>Moderate to Severe Asthma</td>
<td>150 mg vials</td>
<td>50242-0040-62</td>
<td>3 vials</td>
</tr>
<tr>
<td>Xolair Omalizumab</td>
<td>Chronic Urticaria</td>
<td>150 mg vials</td>
<td>50242-0040-62</td>
<td>2 vials</td>
</tr>
</tbody>
</table>

Xolair® (Omalizumab)
UnitedHealthcare Commercial Medical Benefit Drug Policy
Proprietary Information of UnitedHealthcare. Copyright 2019 United HealthCare Services, Inc.
CLINICAL EVIDENCE

Proven

Allergic Asthma

Omalizumab is indicated for treatment of adults and adolescents 6 years of age and older, who have moderate to severe persistent asthma and a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.³

Deschildre et al evaluated omalizumab efficacy and safety in a real-life setting in children aged 6 to 18 years (n=104) with severe asthmatics followed up in pediatric pulmonary tertiary care centers.²⁶ Asthma control levels, exacerbations, inhaled corticosteroid dose, lung function and adverse events were evaluated over 1 year. Children were characterized by allergic sensitization to three or more allergens (66%), high IgE levels (mean 1125 kU · L(-1)), high rate of exacerbations (4.4 per year) and healthcare use during the previous year, and high inhaled corticosteroid dose (mean 703 μg equivalent fluticasone per day). Asthma control levels defined as good, partial or poor, improved from 0%, 18% and 82% at entry to 53%, 30% and 17% at week 20, and to 67%, 25% and 8% at week 52, respectively (p<0.0001). Reported exacerbation and hospitalization rates decreased by 72% and 88.5%, respectively. At 12 months, forced expiratory volume in 1 s (FEV1) improved by 4.9% (p=0.023), and inhaled corticosteroid dose decreased by 30% (p<0.001). Six patients stopped omalizumab for related significant adverse events. Omalizumab improved asthma control in children with severe allergic asthma and was generally well tolerated. Authors concluded that he observed benefit was greater than that reported in clinical trials.

Sorkness et al conducted a post-hoc analyses which examined patient characteristics of those eligible and ineligible for omalizumab; described onset of effect after initiation of omalizumab and offset of treatment effect after stopping therapy; and determined whether the efficacy differs by age, asthma severity, dosing regimen, and pre-specified biomarkers.²⁷ Inner-city children and adolescents with persistent allergic asthma enrolled in the Inner-City Anti-IgE Therapy for Asthma (ICATA) trial that compared omalizumab with placebo added to guidelines-based therapy for 60 weeks were eligible for the evaluation (a significant portion of children and adolescents particularly suited for omalizumab because of asthma severity status were ineligible due to IgE >1300 IU/mL). Two hundred ninety-three of 889 participants (33%) clinically suitable for omalizumab were ineligible for dosing according to a modified dosing table specifying IgE level and body weight criteria. Baseline symptoms were comparable among those eligible and ineligible to receive omalizumab, but other characteristics (rate of health care utilization and skin test results) differed. Patients receiving biweekly injections experienced a greater reduction in both exacerbations (OR = 2.54) and inhaled corticosteroids (ICS) usage (−204.8 μg/day) compared to patients receiving monthly injections (1.42 and −50.2 μg/day; p=0.08 and p=0.02, respectively). Omalizumab efficacy for symptom days per 2 weeks did not differ by dosing regimen (p=0.62). Patients with total IgE ≥700 IU/mL had the greatest reduction in ICS usage (−504.6 μg/day) because of treatment with omalizumab. The time of onset of omalizumab effect was <30 days and time of offset was between 30 and 120 days. No difference in efficacy was noted by age or asthma severity, but high exhaled nitric oxide, blood eosinophils, and body mass index predicted efficacy. Researchers concluded that results of this analysis showed that efficacy for exacerbations and ICS treatment was comparable in children 6 to 12 years of age compared with older children (>12 years). Additionally, the data suggested that omalizumab may be efficacious in both severe disease (steps 5-6 treatments) and more moderate disease (steps 1-4). Certain subgroups of persons, for example, those with higher exhaled nitric oxide, blood eosinophils, and BMI were more likely to benefit from omalizumab according to the secondary analysis.

The Inner-City Anti-IgE Therapy for Asthma (ICATA) Study was a 60-week, randomized, double-blind, placebo-controlled, parallel-group trial (n=419) which evaluated the effectiveness of omalizumab (75-375 mg subcutaneously every 2-4 weeks), as compared with placebo, when added to guidelines-based therapy.²¹ The primary outcome was reduction in symptoms and exacerbations of asthma. Inner-city patients 6 to 20 years of age with persistent asthma (receiving long-term therapy for disease control and having symptoms of persistent asthma or evidence of uncontrolled disease as indicated by hospitalization or unscheduled urgent care in the 6 to 12 months preceding study entry), at least one positive skin test for a perennial allergen, weight between 20 and 150 kg, and having total serum levels of IgE between 30 and 1300 IU per milliliter were eligible for enrollment. Additionally, patients not receiving long-term control therapy were eligible for enrollment only if they had both persistent symptoms and uncontrolled asthma. The primary outcome defined as reduction in symptoms (number of days with symptoms during the previous two weeks) and exacerbations of asthma was evaluated every 4 weeks. Omalizumab as compared with placebo significantly reduced the number of days with asthma symptoms, from 1.96 to 1.48 days per 2-week interval, a 24.5% decrease (p<0.001). Similarly, the percentage of participants with exacerbations (one or more) during the study was 48.8% in the placebo group compared with 30.3% in the omalizumab group (p<0.001), and the percentage who were hospitalized because of asthma was 6.3% as compared with 1.5%, respectively (p=0.02). Improvements occurred with omalizumab despite reductions in the use of inhaled glucocorticoids and long-acting beta-agonists.
In a further pre-specified, subgroup [Lanier 2009] analysis, Kulus et al. evaluated efficacy and safety of omalizumab as compared to placebo in children (n=235) with severe, persistent allergic asthma. Over the 24-week fixed-steroid phase, omalizumab reduced the rate of clinically significant asthma exacerbations (worsening symptoms requiring doubling of baseline inhaled corticosteroid dose and/or systemic steroids) by 34% versus placebo (0.42 vs 0.63, p=0.047). Over 52 weeks, the exacerbation rate was reduced by 50% (p<0.001). The overall incidence of adverse events (AEs) was similar in both omalizumab and placebo groups (93.4% vs 95.0%, p=0.779), serious AEs were less frequent in the omalizumab group (3.6% vs 10.0%, p=0.073), and no new safety concerns were evident. Researchers noted that the sample size was not based on providing statistical power in the severe subgroup, and no corrections were made for multiple comparisons; however, outcomes consistently favored omalizumab.

Milgrom et al. evaluated the safety of omalizumab in children (n=926) ages 6-12 with allergic (IgE-mediated) asthma in a pooled analysis of two double-blind, placebo controlled studies [Milgrom 2001 and Lanier 2009]. Children on optimized asthma care were randomized (2:1) to omalizumab (75-375 mg every 2 or 4 weeks) or placebo. Adverse events (AEs) were more frequently reported in the placebo (91.7%) than omalizumab (89.7%) group. The most common AEs were nasopharyngitis, upper respiratory tract infection and headache. Suspected treatment-related AEs included headache, erythema and urticaria; none of which were reported by ≥ 2% of patients receiving omalizumab. Serious adverse effects were reported by 3.4% and 6.6% of patients receiving omalizumab and placebo, respectively; the most common were appendicitis, pneumonia and bronchitis; no deaths were reported.

**Allergic Asthma with IgE Levels > 700 IU/ml**

A retrospective study evaluated the response of asthmatic patients treated with omalizumab with IgE levels greater than 700 IU/mL. Emergency department (ED) visits, hospitalizations, change in forced expiratory volume in 1 second (FEV1), corticosteroid bursts, and Asthma Control Test (ACT) scores were recorded for a period of 6 months before and after treatment with omalizumab in patients with elevated IgE levels or treatment length of ≥ 6 months. Twenty-six patients with an IgE level > 700 IU/mL (group 1) were matched by age, sex, and severity of asthma to patients with an IgE of 30 to 700 IU/mL (group 2). The mean numbers of ED visits before and after treatment was 0.96 vs 0.23 (p=0.008) in group 1 and 0.65 vs 0.15 (p=0.02) in group 2. Both groups had an improvement in asthma control based on the mean ACT score before and after treatment (15.6 vs 18.9 [p=0.02] and 15.4 vs 19 [p=0.006], respectively). Additionally, there was a significant reduction in the frequency of systemic corticosteroid use during the 6 months before and after the treatment (2.58 vs 0.96 [p < 0.001] and 2.62 vs 1.23 [p < 0.001] systemic steroid treatments, respectively). Researchers concluded that omalizumab was just as effective in reducing ED visits, controlling asthma symptoms, and reducing the need for systemic corticosteroids in patients with IgE levels > 700 IU/mL compared with patients with levels within 30 to 700 IU/mL.

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluated use of high dose omalizumab in adult patients with IgE levels > 700 IU/mL. Fifty asthmatic patients (pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 65% predicted; had been asthma exacerbation-free for ≥ 4 weeks; and skin reactivity to a specific allergen within 2 years before screening) with an age range of 18 to 65 years and a body weight range of 40 to 150 kg were divided into two groups according to IgE levels (group 1: 30-300 IU/mL and group 2: > 700-2000 IU/mL) and randomized 2:1 to receive either omalizumab or placebo every 2 or 4 weeks. Allergen bronchoprovocation (ABP) testing was performed at baseline, week 8 and week 16. The primary efficacy endpoint measured was the early-phase allergic response (EAR; defined as the maximum percentage drop in forced expiratory volume in 1 second during the first 30 minute after ABP). Secondary outcome evaluated with the late-phase allergic response (LAR; defined as maximum percentage drop in FEV1 over 3-8 hours after ABP). Additional outcomes assessed included serum free IgE (as a pharmacodynamic endpoint) and the exhaled fractional concentration of nitric oxide (FENO; as an exploratory endpoint). At week 8, EAR was 23.1% for placebo and treatment with omalizumab reduced it to 9.3% in in group 1 (p=0.018 vs placebo) and 5.6% in group 2 (p<0.001 vs placebo). Additionally, at week 16, reported EAR was 20%, 11.8% (p=0.087) and 5.1% (p<0.001), respectively. LAR analysis was not performed due to the small number of patients studied. Serum free IgE levels decreased in groups 1 and 2 and remained <50 ng/ml in all patients during weeks 6-16. Treatment with omalizumab suppressed FENO increases after ABP in both groups. Authors conclude that the outcomes of this study demonstrated that the protective effects of omalizumab against allergen-induced bronchoconstriction in patients with allergic asthma and baseline IgE up to 2000 IU/ml.

Researchers conducted a post-marketing observational surveillance trial to evaluate the efficacy and tolerability of omalizumab in a real-life setting in Spain, particularly in those patients with immunoglobulin E (IgE) levels out of range. Patients were recruited if they had a diagnosis of uncontrolled severe, persistent, allergic asthma while on high-dose inhaled corticosteroids (ICSs) plus long-acting B2-agonist (LABA); had an age ≥ 12 years; and had received at least one dose of omalizumab between May 2006 and November 2009, Main efficacy outcomes evaluated included asthma exacerbation rate (AER), asthma control test (ACT), and global evaluation of treatment effectiveness (GETE). Of the 266 patients enrolled, 7 patients had IgE levels < 30 IU/ml and 46 patients had IgE levels > 700 IU/ml. Average AER reported for all groups showed a reduction from 3.6 in previous year to 0.67 at 4 months (p<0.05) and to 1.04 at 2 years (p<0.05). Average ACT increased from 14.3 at baseline to 18.4 at 4 months (p<0.05) and to 20.3...
p<0.05) at 2 years. After 4 months, 74.6% of patients had reached a good or excellent rate on the GETE scale (p<0.05) and this rate continued to increase to 81.6% at 2 years. Similarly, in the IgE > 700 IU/ml group, researchers reported an increased ACT from 13.6 at baseline to 20.9 at the 2-year visit (p<0.05) and a decrease in exacerbations from 3.58 at baseline to 0.72 at the 2-year visit (p<0.05). At follow-up, maintenance treatment with oral steroids was reduced from 89 patients to 19 patients (p<0.05). Omalizumab was discontinued because of lack of efficacy in 28/266 (10.5%) patients and 30 patients (11.4%) reported adverse events (none were severe). Researchers conclude that this observational study confirms that omalizumab is efficacious and well tolerated in patients with uncontrolled severe asthma, including those patients with IgE levels > 700 IU/ml.

**Chronic Urticaria**

Omalizumab is indicated for treatment of chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment.¹

Saini et al conducted a 40-week, randomized, double-blind, placebo-controlled trial (ASTERIA I) to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients (n=319) with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1 antihistamine treatment.¹ Eligible patients aged 12–75 years with CIU/CSU who remained symptomatic despite treatment with approved doses of H1 antihistamines were randomized (1:1:1:1) in a double-blind manner to subcutaneous omalizumab 75 mg (n=78), 150 mg (n=80), or 300 mg (n=81) or placebo (n=80) every 4 weeks for 24 weeks followed by 16 weeks of follow-up. The primary outcome measured was change from baseline in weekly itch severity score (ISS) at week 12. Secondary outcomes evaluated at week 12, included changes from baseline in UAS7 and weekly number of hives score; time to MID response (≥50-point decrease) in weekly ISS; the proportion of patients with UAS7≥6; the proportion of weekly ISS MID responders; changes from baseline in weekly size of largest hive score and overall DLQI score; the proportion of angioedema-free days during weeks 4 to 12; and the proportion of patients with complete response (UAS7=0). Compared with placebo mean weekly ISS was reduced from baseline to week 12 by an additional 2.96 points (95% confidence interval (CI): -4.71 to -1.21; p=0.0010), 2.95 points (95% CI: -4.72 to -1.18; p=0.0012), and 5.80 points (95% CI: -7.49 to -4.10; p<0.0001) in the omalizumab 75-mg, 150-mg, and 300-mg groups, respectively. The omalizumab 300-mg group met all nine secondary end points, including a significant decrease in the duration of time to reach minimally important difference response (≥50-point decrease) in weekly ISS (p<0.0001) and higher percentages of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) ≤ 5: 15.9% vs. 11.3% p<0.0001) and complete response (UAS7=0: 35.8% vs. 8.8% p<0.0001) versus placebo. During the 24-week treatment period, the proportions of patients who experienced one or more treatment-emergent adverse events (AEs) ranged from 57 to 69% in the omalizumab groups versus 51% in the placebo group. Additionally, 2 (2.9%), 3 (3.4%), 0, and 4 (5.0%) patients in the omalizumab 75-mg, 150-mg, 300-mg, and placebo groups, respectively, experienced a serious adverse event. Omalizumab 300 mg administered every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU patients who remained symptomatic despite treatment with approved doses of H1 antihistamines. Additionally, the results of this study showed a sustained treatment effect of omalizumab 300 mg for up to 24 weeks on CIU/CSU symptom scores in patients with H1 antihistamine-refractory CIU/CSU. The safety profile for omalizumab over 24 weeks of treatment in patients with CIU/CSU receiving approved doses of H1 antihistamines was consistent with the established safety profile in allergic asthma and with previous observations in CIU/CSU.

**Unproven**

**Seasonal Allergic Rhinitis**

Researchers conducted a systemic review and meta-analysis of the efficacy and safety of omalizumab in poorly controlled allergic rhinitis in randomized controlled trials dating through 2013.¹⁸ Eleven studies that assessed 2870 randomized patients were included. A statistically significant reduction in the daily nasal symptom severity score (standardized mean difference -0.67 [95% CI, -1.3 to -0.31]; p< .0001; I(2), 92%) and a statistically significant reduction in daily nasal rescue medication score (-0.22 [95% CI, -0.39 to -0.05]; p=0.01; I(2), 58%) were observed. There was not a statistically significant difference in the occurrence of any adverse event (relative risk 1.06 [95% CI, 0.94-1.19; I(2), 55%]). The meta-analysis showed that, in seasonal and perennial allergic rhinoconjunctivitis, treatment with omalizumab provided an improvement of the daily nasal symptom severity score (DNSSS) and a reduction of antiallergic medication use compared with placebo. The rhinosinusitis-related quality of life (rQoL) appeared to be improved in the limited randomized evidence available. The observed safety profile indicated an adequate tolerability and a comparable overall AEs pattern. The potential benefits of omalizumab need to be considered in the context of costs of therapy and rare AEs. Larger clinical trials and economic studies are needed to address issues of rare events occurrence and cost-effectiveness, respectively.

Several studies have evaluated the use of omalizumab therapy in children, adolescents and adults with seasonal allergic rhinitis. Though results appear to be promising, additional trials are warranted to establish long-term efficacy and safety, as well as appropriate dosage and timing.⁶-¹¹
**Perennial Allergic Rhinitis**

Corren et al. assessed 19 patients (ages 18-65 years) with perennial allergic rhinitis in a 26 week open-label study of intravenous (IV) omalizumab 0.015-0.030 mg/kg/IgE [IU/mL] every 2 weeks.\(^12\) Serum free IgE concentrations decreased by up to 99%. Nasal allergen challenge symptom scores (e.g. sneezing, rhinorrhea) decreased significantly.

In another study, 40 patients with perennial allergic rhinitis receiving open-label omalizumab 0.015-0.030 mg/kg/IgE [IU/mL] IV every 2 weeks for 28 weeks showed up to 99% decrease in serum free IgE and decreased reaction to wheal-and-flare skin tests at day 98.\(^13\) However, upon decreased dosage to 0.0015-0.005mg/kg/IgE [IU/mL] for another 18 weeks, serum free IgE and skin test reactivity increased significantly and returned to baseline upon discontinuation.

Chervinsky et al. studied the efficacy, safety, and tolerability of omalizumab in the short-term treatment of patients 12 to 70 years of age with perennial allergic rhinitis with moderate to severe symptoms in a randomized, double-blind trial.\(^14\) The patients completed 16 weeks of either placebo (n=145) or at least 0.016 mg/kg/IgE [IU/mL] subcutaneous omalizumab every four weeks (n=144). Patients maintained a diary of their daily symptoms including nasal severity scores throughout the study period, which was based on a 4-point scale (0 = no symptoms to 3 = severe symptoms). Patients in the omalizumab group had a 69% reduction in the average daily nasal severity score from baseline compared to 49% of the placebo treated patients (p=0.001). Symptoms were controlled, which was defined as a score of less than 0.75 on a 4 point scale, in 28% (40/143) of patients in the omalizumab group compared to 10% (14/145) of patients in the placebo group. In both study groups, antihistamine use was low, however omalizumab significantly decreased antihistamine use per month more than placebo (omalizumab; 4.5 to 1.5 days per month, placebo: 3.6 to 2.7 days per month, p=0.005). Three patients in each group dropped out due to intolerance of study medication or placebo, but no severe safety concerns were noted throughout the study. In this study, there was a large placebo effect making the true effect of omalizumab difficult to determine. Additional and larger studies are needed in this population.

**Atopic Dermatitis**

Heil et al. investigated the effects of omalizumab or placebo on the expression of IgE and its receptors on cells and on serum components of patients with atopic dermatitis (AD).\(^25\) Additional evaluation included whether omalizumab would revert preexisting lesions in patients with long lasting and ongoing AD. Twenty patients were randomized 2:1 in a placebo-controlled, double blind study for 16 weeks. Male and female patients (ages 12-60 years) with a clinical diagnosis of AD and a serum IgE between 30 and 1300 IU/ml were included. Patients in the omalizumab treatment had reduced serum levels of free IgE and decreased reaction to atopy patch test results in single patients.

Researchers conclude that atopic dermatitis patients had reduced serum levels of free IgE and dec

**Peanut Allergy**

In a phase II, double-blind, randomized clinical trial, omalizumab was evaluated in patients with a hypersensitivity reaction to peanut and compared with placebo.\(^17\)-\(^19\) During screening, patients underwent a double-blind oral food challenge with either peanut flour or wheat flour. Patients who reacted to less than or equal to 250 mg of peanut flour and not wheat flour were randomized to omalizumab (minimum 0.016 mg/kg/IgE [IU/mL] every 4 weeks or 0.008 mg/kg/IgE [IU/mL] every 2 weeks) or placebo for 20 to 22 weeks. At 24 weeks, patients were to receive a second double-blind oral challenge to either peanut or wheat flour. However, due to safety concerns of the oral food challenge, an external data and safety monitoring committee terminated the trial early.

**Acute Bronchospasm or Status Asthmaticus**

The US Food and Drug Administration (FDA) has required the manufacturer of omalizumab to state in its labeling that Xolair cannot be used to treat acute bronchospasm or status asthmaticus.\(^3\)

**Professional Societies**

**Allergic Asthma**

The Global Initiative for Asthma (GINA, 2018) recommends that patients 6 years and older may be treated with omalizumab as follows (Evidence A: Randomized controlled trials and meta-analyses. Rich body of evidence):\(^2\)

- Suggested add-on treatment for patients ≥ 6 years with moderate or severe allergic asthma that is uncontrolled on Step 4 treatment (Evidence A)
- Patients ≥ 6 years with severe allergic asthma with elevated IgE levels may benefit from omalizumab (anti-IgE) therapy (Evidence A)

In April 2013, The National Institute for Health and Care Excellence (NICE) published a technology appraisal guidance addressing use of omalizumab in children aged 6 to 11 years with severe, persistent asthma.\(^4\) In the assessment, NICE noted the ‘life-changing’ effect of omalizumab reported by patients and concluded that omalizumab as an add-on
to optimised standard therapy is more clinically effective in treating severe persistent allergic asthma than optimised standard therapy alone, leading to a reduction in total emergency visits (including hospital admissions, A&E visits and unscheduled general physician visits) in adults, reduced hospital admissions in children, improved lung function in adults and a reduction in the frequency and use of rescue medication and oral corticosteroids. The committee recommended that omalizumab be used as follows:

- Omalizumab is recommended as an option for treating severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimized standard therapy [defined - as a full trial of (and, if tolerated, documented compliance with) inhaled high-dose corticosteroids, long-acting ß2-agonists, leukotriene receptor antagonists, theophylline, oral corticosteroids and smoking cessation if clinically appropriate].
- In people aged 6 years and older who need continuous or frequent treatment with oral corticosteroids (defined as 4 or more courses in the previous year)
  - Optimized standard therapy is defined as a full trial of and, if tolerated, documented compliance with inhaled high-dose corticosteroids, long-acting beta2 agonists, leukotriene receptor antagonists, theophyllines, oral corticosteroids, and smoking cessation if clinically appropriate.

In June 2015, NICE published an additional technology appraisal guidance addressing use of omalizumab in children and adults aged 12 years and over for the treatment of spontaneous urticaria. The committee recommended that omalizumab be used as follows:

- Omalizumab is recommended as an option as add-on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:
  - the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or more
  - the person’s condition has not responded to standard treatment with H1-antihistamines and leukotriene receptor antagonists
  - omalizumab is stopped at or before the fourth dose if the condition has not responded
  - omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses
  - omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy

**Chronic Urticaria**

In 2014, the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology updated the practice parameter for the diagnosis and management of acute and chronic urticaria (CU). The practice parameter established a step-care approach to the treatment of chronic urticaria and angioedema. The task force recommended the following step-care treatment approach:

- Monotherapy with second-generation antihistamines: H1-antagonists are effective in the majority of patients with CU but might not achieve complete control in all patients.
- Dose advancement of H1-antihistamine therapy, combining first- and second-generation agents and adding an H2-antihistamine and/or an antileukotriene agent: Higher doses of second-generation antihistamines can provide greater efficacy when control is not achieved with conventional doses of these agents.
- Therapeutic trial of potent antihistamine (e.g., hydroxyzine or doxepin): First-generation antihistamines should be prescribed cautiously in the elderly or patients with occupations (e.g., machine operators, airline pilots, or alpine skiers) for which alertness is essential.
- Add an immunosuppressant or biologic agent: Omalizumab and cyclosporine have the greatest published experience documenting efficacy in patients with CU compared with all other alternative agents.

**CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)**

Medicare does not have a National Coverage Determination (NCD) for Xolair (Omalizumab). Local Coverage Determinations (LCDs) exist; see the LCDs for Drugs and Biologics (Non-chemotherapy) and Omalizumab (Xolair®).

In general, Medicare covers outpatient (Part B) drugs that are furnished “incident to” a physician’s service provided that the drugs are not usually self-administered by the patients who take them. See the Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals.

(Accessed June 17, 2018)

**REFERENCES**


<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/01/2019</td>
<td>Off cycle review. Revised criteria regarding combination therapy. Approved by the National Pharmacy &amp; Therapeutics Committee on 12/19/2018. Policy 2018D0033N archived.</td>
</tr>
<tr>
<td>09/01/2018</td>
<td>Annual review. Minor revision to coverage rationale. Updated CMS statement and references. Removed ICD-10 codes J45.20, J45.21, J45.30, J45.31. Approved by the National Pharmacy and Therapeutics Committee on 08/17/2018. Policy 2017D0033M archived.</td>
</tr>
<tr>
<td>12/01/2017</td>
<td>Annual review. Revised coverage rationale to specify clinical response criteria and authorization period. Updated Clinical Evidence, CMS Statement, and references. Updated applicable codes to include maximum dosage requirements based on prescribing information and diagnosis. Approved by the National Pharmacy and Therapeutics Committee on 08/18/2017. Policy 2016D0033L archived.</td>
</tr>
<tr>
<td>02/01/2016</td>
<td>Removed 708.9, 493.92 and J45.901. Added L50.0 &amp; L50.1. Policy 2015D0033J archived.</td>
</tr>
<tr>
<td>08/01/2015</td>
<td>Annual review. Minor formatting revisions (removed 'refer to benefit considerations for specific state guidance') but no changes to clinical criteria in Coverage Rationale.</td>
</tr>
<tr>
<td>Date</td>
<td>Action/Description</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09/01/2014</td>
<td>Updated Benefits, Clinical Evidence and References. Approved by the National Pharmacy and Therapeutics Committee on 05/20/2015. Policy 2014D0033H archived.</td>
</tr>
<tr>
<td>07/01/2013</td>
<td>Policy revised per annual review. Expanded IgE level requirement for asthma and clarified medical necessity criteria. Added new criteria for asthma in children age 6 &lt; 12 years of age. Updated chronic urticaria requirement to include symptomatic despite H1 antihistamine treatment. Updated Clinical Evidence, U.S. FDA, and References. Added codes 708.0, 708.1 &amp; 708.9. Approved by the National Pharmacy and Therapeutics Committee on 07/08/2014. Policy 2013D0033G archived.</td>
</tr>
<tr>
<td>04/01/2013</td>
<td>Policy updated per annual review, approved by National Pharmacy and Therapeutics Committee on 02/19/2013. Added medical necessity criteria. Updated Clinical Evidence. Policy 2012D0033D archived.</td>
</tr>
<tr>
<td>09/01/2012</td>
<td>Added list of applicable ICD-10 codes (preview draft) in preparation for the transition from ICD-9 to ICD-10 medical coding on 10/01/2014.</td>
</tr>
<tr>
<td>04/01/2012</td>
<td>Policy updated per annual review, approved by National Pharmacy and Therapeutics Committee on 02/21/2012. Added chronic urticaria to list of unproven uses. Updated Clinical Evidence. Policy 2011D0033A archived.</td>
</tr>
<tr>
<td>08/01/2011</td>
<td>Clarified drug policy. Removed “to support medical necessity review where applicable” from Additional Information. Updated Clinical Evidence. Removed all unproven ICD-9 codes from the policy because standard policy format is to list only proven ICD-9 codes [477.0, 477.1, 477.2, 477.8, 477.9, 493.01, 493.11, 493.21, 493.91, 519.11, 691.0, 691.8, 692.9, V15.01].</td>
</tr>
<tr>
<td>06/07/2011</td>
<td>Policy updated per annual review, approved by National Pharmacy and Therapeutics Committee on 03/08/2011. Created an Additional Information section within the Coverage Rationale to address the IgE level upon which dosing is calculated. Added acute bronchospasm and status asthmaticus to the list of unproven uses. Added Benefits Consideration section. Updated Clinical Evidence. Removed deleted CPT codes 90769 and 90772. Moved 493.01, 493.11, 493.21 and 493.91 to unproven codes. Added 519.11 to unproven codes. Updated references. Policy 2010D0033C archived.</td>
</tr>
<tr>
<td>12/30/2009</td>
<td>Added ICD-9s 493.00, 493.10, and 493.90. Removed ICD-9 495.9.</td>
</tr>
<tr>
<td>08/24/2009</td>
<td>Added in vitro reactivity to criteria for allergen response.</td>
</tr>
<tr>
<td>03/11/2008</td>
<td>Diagnosis list updated per instructions from Coding and Integrity.</td>
</tr>
<tr>
<td>03/10/2008</td>
<td>New policy</td>
</tr>
</tbody>
</table>